ALK and breast carcinoma: For example, trastuzumab and crizotinib have both demonstrated survival advantage in human epidermal growth factor receptor 2 (HER2)‐positive breast cancer and anaplastic lymphoma kinase (ALK) positive non‐small‐cell lung cancer, respectively 17, 18.